A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects.
The erythropoietic response to graded doses of recombinant human erythropoietin (epoetin alfa) was assessed in 24 hemodialysis patients by quantitative ferrokinetic studies, and measurement of the reticulocyte count and plasma levels of transferrin receptor protein. These responses were compared to those of 22 normal subjects. Epoetin alfa was given intravenously at 15, 50 or 150 U/kg every other day for four injections. Three patients with chronic renal failure were restudied after renal function was restored following renal transplantation. The results of these three different measurements of erythroid function showed that the acute response to recombinant human erythropoietin was similar in normal subjects and patients with renal failure. We conclude that chronic uremia does not alter the responsiveness to erythropoietin in vivo.
Eschbach
J W
JW
Department of Medicine, University of Washington, Seattle.
Haley
N R
NR
Egrie
J C
JC
Adamson
J W
JW
D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D004906:Erythrocyte Count; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D007501:Iron / Q000097:blood; D011990:Receptors, Transferrin / Q000378:metabolism; D006435:Renal Dialysis; D012156:Reticulocytes; D014511:Uremia / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D011990:Receptors, Transferrin; D004921:Erythropoietin; D007501:Iron